Overview

Elranatamab in R/R Multiple Myeloma

Status:
Recruiting

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Pfizer